Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma.

ABSTRACT:

Introduction

Adult T-cell leukemia-lymphoma (ATL) is a mature T-cell lymphoproliferative neoplasm caused by human T-cell leukemia virus type-1 infection. There is no standard treatment for relapsed or refractory (r/r) ATL, and clinical outcomes are poor. This systematic review examined the survival outcomes for r/r ATL treated with various systemic therapies.

Methods

EMBASE and PubMed were searched for studies on r/r ATL, published between January 2010 and January 2020. The main outcome of interest was overall survival (OS). Median OS and an exploratory 30% OS time were assessed based on published data and Kaplan-Meier curves.

Results

There were 21 unique treatment subgroups (from 14 studies), that met the eligibility criteria. Nine subgroups were mogamulizumab treatm

SUBMITTER: Nosaka K 

PROVIDER: S-EPMC9299810 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature